69 results on '"Beck Popovic M"'
Search Results
2. Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE
- Author
-
Maria, O, Eva, B, Pamela R, K, Olga, K, Marko, O, Reineke A, S, Gilles, V, Achini, F, Balduzzi, A, Beck Popovic, M, Beishuizen, A, Bergamaschi, L, Biondi, A, Bourdeaut, F, Braicu, E, Brok, J, Brugières, L, Burke, A, Calaminus, G, Casanova, M, Choucair, M, Cleirec, M, Corbaciouglu, S, Genoveva Correa Llano, M, De Rojas, T, Domínguez Pinilla, N, Elmaraghi, C, Ferrari, A, Fossa, A, Gaspar, N, Herold, N, Karapiperi, K, Karu, M, Kjærsgaar, M, Knörr, F, Koenig, C, Kranjcec, I, Krawczyk, M, Lehmberg, K, Lehrnbecher, T, Lunesink, M, Massano, D, Matijasic, N, Merks, H, Metzler, M, Michalski, A, Minkov, M, Morland, B, Niktoreh, N, Oltenau, E, Orbach, D, Owens, C, Papachristidou, S, Pasqualini, C, Pavlovic, M, Perez Albert, P, Poyer, F, Radulovic, I, Reinhardt, D, Rebelo, J, Roser, E, Russo, I, Scheinemann, K, Schindera, C, Schrappe, M, Sehested, A, Sehouli, J, Spreafico, F, J Strauss, S, Stutterheim, J, Svojgr, K, Tzotzola, V, Van Ewijk, R, Verschuur, A, Vora, A, Woessmann, W, Zajac-Spychala, O, Zwaan, M, Otth, Maria, Brack, Eva, Kearns, Pamela R, Kozhaeva, Olga, Ocokoljic, Marko, Schoot, Reineke A, Vassal, Gilles, Federica Achini, Adriana Balduzzi, Maja Beck Popovic, Auke Beishuizen, Luca Bergamaschi, Andrea Biondi, Franck Bourdeaut, Elena Braicu, Jesper Brok, Laurence Brugières, Amos Burke, Gabriele Calaminus, Michela Casanova, Marie-Louise Choucair, Morgane Cleirec, Selim Corbaciouglu, Maria Genoveva Correa Llano, Teresa De Rojas, Nerea Domínguez Pinilla, Caroline Elmaraghi, Andrea Ferrari, Alexander Fossa, Nathalie Gaspar, Nikolas Herold, Kyriaki Karapiperi, Maarja Karu, Mimi Kjærsgaar, Fabian Knörr, Christa Koenig, Izabela Kranjcec, Malgorzata Krawczyk, Kai Lehmberg, Thomas Lehrnbecher, Maaike Lunesink, Davide Massano, Nuša Matijasic, Hans Merks, Markus Metzler, Anthony Michalski, Milen Minkov, Bruce Morland, Naghmeh Niktoreh, Elena Oltenau, Daniel Orbach, Cormac Owens, Smaragda Papachristidou, Claudia Pasqualini, Maja Pavlovic, Paula Perez Albert, Fiona Poyer, Ivana Radulovic, Dirk Reinhardt, Joana Rebelo, Eva Roser, Ida Russo, Katrin Scheinemann, Christina Schindera, Martin Schrappe, Astrid Sehested, Jalid Sehouli, Filippo Spreafico, Sandra J Strauss, Janine Stutterheim, Karel Svojgr, Vasiliki Tzotzola, Roelof Van Ewijk, Arnauld Verschuur, Ajay Vora, Willi Woessmann, Olga Zajac-Spychala, Michel Zwaan, Maria, O, Eva, B, Pamela R, K, Olga, K, Marko, O, Reineke A, S, Gilles, V, Achini, F, Balduzzi, A, Beck Popovic, M, Beishuizen, A, Bergamaschi, L, Biondi, A, Bourdeaut, F, Braicu, E, Brok, J, Brugières, L, Burke, A, Calaminus, G, Casanova, M, Choucair, M, Cleirec, M, Corbaciouglu, S, Genoveva Correa Llano, M, De Rojas, T, Domínguez Pinilla, N, Elmaraghi, C, Ferrari, A, Fossa, A, Gaspar, N, Herold, N, Karapiperi, K, Karu, M, Kjærsgaar, M, Knörr, F, Koenig, C, Kranjcec, I, Krawczyk, M, Lehmberg, K, Lehrnbecher, T, Lunesink, M, Massano, D, Matijasic, N, Merks, H, Metzler, M, Michalski, A, Minkov, M, Morland, B, Niktoreh, N, Oltenau, E, Orbach, D, Owens, C, Papachristidou, S, Pasqualini, C, Pavlovic, M, Perez Albert, P, Poyer, F, Radulovic, I, Reinhardt, D, Rebelo, J, Roser, E, Russo, I, Scheinemann, K, Schindera, C, Schrappe, M, Sehested, A, Sehouli, J, Spreafico, F, J Strauss, S, Stutterheim, J, Svojgr, K, Tzotzola, V, Van Ewijk, R, Verschuur, A, Vora, A, Woessmann, W, Zajac-Spychala, O, Zwaan, M, Otth, Maria, Brack, Eva, Kearns, Pamela R, Kozhaeva, Olga, Ocokoljic, Marko, Schoot, Reineke A, Vassal, Gilles, Federica Achini, Adriana Balduzzi, Maja Beck Popovic, Auke Beishuizen, Luca Bergamaschi, Andrea Biondi, Franck Bourdeaut, Elena Braicu, Jesper Brok, Laurence Brugières, Amos Burke, Gabriele Calaminus, Michela Casanova, Marie-Louise Choucair, Morgane Cleirec, Selim Corbaciouglu, Maria Genoveva Correa Llano, Teresa De Rojas, Nerea Domínguez Pinilla, Caroline Elmaraghi, Andrea Ferrari, Alexander Fossa, Nathalie Gaspar, Nikolas Herold, Kyriaki Karapiperi, Maarja Karu, Mimi Kjærsgaar, Fabian Knörr, Christa Koenig, Izabela Kranjcec, Malgorzata Krawczyk, Kai Lehmberg, Thomas Lehrnbecher, Maaike Lunesink, Davide Massano, Nuša Matijasic, Hans Merks, Markus Metzler, Anthony Michalski, Milen Minkov, Bruce Morland, Naghmeh Niktoreh, Elena Oltenau, Daniel Orbach, Cormac Owens, Smaragda Papachristidou, Claudia Pasqualini, Maja Pavlovic, Paula Perez Albert, Fiona Poyer, Ivana Radulovic, Dirk Reinhardt, Joana Rebelo, Eva Roser, Ida Russo, Katrin Scheinemann, Christina Schindera, Martin Schrappe, Astrid Sehested, Jalid Sehouli, Filippo Spreafico, Sandra J Strauss, Janine Stutterheim, Karel Svojgr, Vasiliki Tzotzola, Roelof Van Ewijk, Arnauld Verschuur, Ajay Vora, Willi Woessmann, Olga Zajac-Spychala, and Michel Zwaan
- Abstract
Background: Shortages and unequal access to anticancer medicines for children and adolescents are a reality in Europe. The aim of the European Society for Paediatric Oncology (SIOPE) Essential Anticancer Medicines Project was to provide a list of anticancer medicines that are considered essential in the treatment of paediatric cancers to help ensure their continuous access to all children and adolescents with cancer across Europe. Methods: This pan-European project, done between Jan 20, 2020, and Feb 18, 2022, was designed to be a systematic collection and review of treatment protocols and strategies that are used to treat childhood cancer in Europe. We formed 16 working groups on the basis of paediatric cancer types, and which were based on the existing SIOPE Clinical Trial Groups. Workings groups consisted of representatives from the SIOPE Clinical Trial Groups, Young SIOPE members, and senior paediatric oncology experts. Each group collected existing treatment protocols that are used to treat the respective cancer types in Europe. Medicines from the standard group of each protocol were extracted. For medicines not on the WHO Essential Medicines List for children (EMLc) 2017, working groups did a literature search to determine whether the medicines should be defined as essential, promising, or neither essential nor promising. Each group provided an individual summary, and all medicines that were considered essential by at least one group were combined in a joint list. Findings: The working groups identified 73 treatment protocols used in Europe and defined 66 medicines as essential. For several newer medicines, such as kinase inhibitors or tisagenlecleucel, the supporting evidence was insufficient to consider them essential, so these medicines were defined as promising. 25 medicines were considered promising by at least one working group. 22 (33%) of the 66 essential and none of the promising medicines were included in the WHO EMLc 2017. The WHO EMLc 2021 included
- Published
- 2022
3. Neuroblastic Tumors of the Adrenal Gland in Elderly Patients: A Case Report and Review of the Literature
- Author
-
Deslarzes, P., Djafarrian, R., Matter, M., La Rosa, S., Gengler, C., Beck-Popovic, M., and Zingg, T.
- Subjects
ganglioneuroblastoma ,preoperative diagnosis ,elderly patient ,follow up ,neuroblastic tumors ,prognosis ,staging ,surgical and medical therapy - Abstract
Neuroblastic neoplasms (NN) include ganglioneuromas (GN), ganglioneuroblastomas (GNB), and neuroblastomas (NB). They generally arise in childhood from primitive sympathetic ganglion cells. Their incidence in adults, especially among elderly, is extremely low. This is the case of a 74-year-old woman with history of abdominal pain, weakness and night sweating since several months. Blood pressure was normal. CT-scan showed a 10 cm left adrenal mass, without other pathologic findings. An open left-sided adrenalectomy was performed. Recovery was uneventful with hospital length of stay of 8 days. Based on morphological, immunohistochemical, and molecular features the diagnosis was a nodular GNB. A positron emission tomography (PET) performed 6 weeks after the resection did not show any residual tumor or distant metastases. The patient was followed-up with annual clinical and radiological exams. This case presentation, associated with a review of the literature, illustrates the importance to include NN in the preoperative differential diagnosis of adrenal tumors in adults and highlights the need for multidisciplinary patient work-up and management.
- Published
- 2022
4. Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG)
- Author
-
Stathopoulos, C., Lumbroso-Le Rouic, L., Moll, A.C., Parulekar, M., Maeder, P., Doz, F., Jenkinson, H., Beck Popovic, M., Chantada, G., and Munier, F.L.
- Subjects
Cancer Research ,Oncology ,external beam irradiation ,intra-arterial chemotherapy ,intravenous chemotherapy ,metastasis ,retinoblastoma ,secondary enucleation ,survival - Abstract
Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric and subjective indications commonly related to disease progression or relapse, disease persistence masking the optic nerve head or treatment-related complications obscuring the fundus view. This absence of evidence-based consensus regarding SE is explained by the continuously moving frontiers of the conservative management as a result of diagnostic and therapeutic advances, as well as by the lack of studies sufficiently powered to accurately stratify the risk of metastasis in conservatively treated patients. In this position paper of the European Retinoblastoma Group (EURbG), we give an overview of the progressive shift in the indications for SE over the past decades and propose guidelines to assist decision-making with respect to when SE becomes imperative or recommended, with corresponding absolute and relative SE indications. Further studies and validation of biologic markers correlated with the risk of metastasis are expected to set more precisely the frontiers of conservative management and thus consensual criteria for SE in the future.
- Published
- 2021
5. Incidence of Retinoblastoma Has Increased: Results from 40 European Countries
- Author
-
Stacey AW, Bowman R, Foster A, Kivelä TT, Munier FL, Cassoux N, Fabian ID, Al Harby L, Alarcón Portabella S, Alia DB, All-Eriksson C, Antonino R, Astbury NJ, Balaguer J, Balwierz W, Barranco H, Bascaran C, Beck Popovic M, Biewald EM, Bobrova N, Bornfeld N, Brichard BG, Blum S, Capra M, Castela G, Catala J, Chantada G, Chernodrinska VS, Cieslik K, Comsa C, Correa Llano MG, Csóka M, De Potter P, Desjardins L, Dragomir MD, Fernández-Teijeiro A, García Aldana D, Gregersen PA, Gomel N, Hadjistilianou T, Hederova S, Hummlen M, Husakova K, Ida R, Ilic VR, Jenkinson H, Kapelushnik N, Kardava T, Keren-Froim N, Kepak T, Khotenashvili Z, Klett A, Krivaitiene D, Latinovic S, Lumbroso L, Lysytsia L, Maka E, Martín Begue N, Midena E, Moll AC, Murgoi G, Naumenko L, Neroev V, Nikitovic M, Olechowski A, Papyan R, Parrozzani R, Parulekar MV, Pawinska-Wasikowska K, Peric S, Pochop P, Polyakov VG, Reddy MA, Ritter-Sovinz P, Saakyan S, Sagoo MS, San Román Pacheco S, Seregard S, Silva S, Sorochynska T, Stathopoulos C, Stirn Kranjc B, Svojgr K, Tamamyan G, Tandili A, Tateshi B, Tekavcic Pompe M, Urbak SF, Ushakova TL, Valeina S, van Hoefen Wijsard M, Veleva-Krasteva NV, Viksnins M, Wackernagel W, Wolley Dod C, Yarovaya VA, Yarovoy AA, Zhilyaeva K, Zondervan M, and Global Retinoblastoma Study Group
- Subjects
Incidence ,Retinoblastoma ,Familial ,Genetic ,Fitness - Published
- 2021
6. Incidence of retinoblastoma has increased: results from 40 European countries
- Author
-
UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, UCL - (SLuc) Service d'ophtalmologie, Stacey AW, BOWMAN R, FOSTER A, KIVELA TT, MUNIER F, CASSOUX N, FABIAN ID, AL HARBY L, ALARCON PORTABELLA S, ALIA DB, ALL ERIKSSON C, ANTONINO R, ASTBURY NJ, BALGAGUER J, BALWIERZ W, BARRANCO H, BASCARAN C, BECK POPOVIC M, BIEWALD EM, BOBROVA N, BORNFELD N, BRICHARD, Bénédicte, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, UCL - (SLuc) Service d'ophtalmologie, Stacey AW, BOWMAN R, FOSTER A, KIVELA TT, MUNIER F, CASSOUX N, FABIAN ID, AL HARBY L, ALARCON PORTABELLA S, ALIA DB, ALL ERIKSSON C, ANTONINO R, ASTBURY NJ, BALGAGUER J, BALWIERZ W, BARRANCO H, BASCARAN C, BECK POPOVIC M, BIEWALD EM, BOBROVA N, BORNFELD N, and BRICHARD, Bénédicte
- Abstract
Incidence of retinoblastoma has increased: results from 40 European countries
- Published
- 2021
7. Corrigendum to 'Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. 'Alive, with good vision and no comorbidity'' [Prog. Retina Eye Res. 73 (2019) 100764]
- Author
-
Munier FL, Beck-Popovic M, Chantada G, Cobrinik D, Kivelä TT, Lohmann D, Maeder P, Moll AC, Carcaboso AM, Moulin A, Schaiquevich P, Bergin C, Dyson PJ, Houghton S, Puccinelli F, Vial Y, Gaillard MC, and Stathopoulos C
- Published
- 2020
8. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. 'Alive, with good vision and no comorbidity' (vol 73, 100764, 2019)
- Author
-
Munier FL, Beck-Popovic M, Chantada G, Cobrinik D, Kivelä TT, Lohmann D, Maeder P, Moll AC, Carcaboso AM, Moulin A, Schaiquevich P, Bergin C, Dyson PJ, Houghton S, Puccinelli F, Vial Y, Gaillard MC, and Stathopoulos C
- Published
- 2020
9. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN -Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group
- Author
-
Ambros IM, Tonini GP, Pötschger U, Gross N, Mosseri V, Beiske K, Berbegall AP, Bénard J, Bown N, Caron H, Combaret V, Couturier J, Defferrari R, Delattre O, Jeison M, Kogner P, Lunec J, Marques B, Martinsson T, Mazzocco K, Noguera R, Schleiermacher G, Valent A, Van Roy N, Villamon E, Janousek D, Pribill I, Glogova E, Attiyeh EF, Hogarty MD, Monclair TF, Holmes K, Valteau-Couanet D, Castel V, Tweddle DA, Park JR, Cohn S, Ladenstein R, Beck-Popovic M, De Bernardi B, Michon J, Pearson ADJ, and Ambros PF
- Subjects
neoplasms - Abstract
For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome.
- Published
- 2020
10. Optimising Urinary Catecholamine Diagnostics for Neuroblastoma Patients
- Author
-
Matser, Y., Verly, I., De Sain-Van der Velden, M., Wieczorek, A., Vicha, A., Ash, S., Pasqualini, C., Beck-Popovic, M., Schleiermacher, G., Canete, A., Owens, C., Ora, I., De Wilde, B., Cangemi, G., Garaventa, A., Grouzmann, E., Papadakis, V., Simon, T., Hero, B., Van Kuilenburg, A., Tytgat, G., Matser, Y., Verly, I., De Sain-Van der Velden, M., Wieczorek, A., Vicha, A., Ash, S., Pasqualini, C., Beck-Popovic, M., Schleiermacher, G., Canete, A., Owens, C., Ora, I., De Wilde, B., Cangemi, G., Garaventa, A., Grouzmann, E., Papadakis, V., Simon, T., Hero, B., Van Kuilenburg, A., and Tytgat, G.
- Published
- 2020
11. Conservative management of retinoblastoma: Challenging orthodoxy without compromising the state of metastatic grace. 'Alive, with good vision and no comorbidity'
- Author
-
Munier FL, Beck-Popovic M, Chantada G, Cobrinik D, Kivelä TT, Lohmann D, Maeder P, Moll AC, Carcaboso AM, Moulin A, Schaiquevich P, Bergin C, Dyson PJ, Houghton S, Puccinelli F, Vial Y, Gaillard MC, and Stathopoulos C
- Subjects
Liquid biopsy ,Retinoblastoma ,Treatment ,Metastasis ,Intravitreal chemotherapy ,Complication ,Intra-arterial chemotherapy ,Intracameral chemotherapy - Abstract
Retinoblastoma is lethal by metastasis if left untreated, so the primary goal of therapy is to preserve life, with ocular survival, visual preservation and quality of life as secondary aims. Historically, enucleation was the first successful therapeutic approach to decrease mortality, followed over 100 years ago by the first eye salvage attempts with radiotherapy. This led to the empiric delineation of a window for conservative management subject to a "state of metastatic grace" never to be violated. Over the last two decades, conservative management of retinoblastoma witnessed an impressive acceleration of improvements, culminating in two major paradigm shifts in therapeutic strategy. Firstly, the introduction of systemic chemotherapy and focal treatments in the late 1990s enabled radiotherapy to be progressively abandoned. Around 10 years later, the advent of chemotherapy in situ, with the capitalization of new routes of targeted drug delivery, namely intra-arterial, intravitreal and now intracameral injections, allowed significant increase in eye preservation rate, definitive eradication of radiotherapy and reduction of systemic chemotherapy. Here we intend to review the relevant knowledge susceptible to improve the conservative management of retinoblastoma in compliance with the "state of metastatic grace", with particular attention to (i) reviewing how new imaging modalities impact the frontiers of conservative management, (ii) dissecting retinoblastoma genesis, growth patterns, and intraocular routes of tumor propagation, (iii) assessing major therapeutic changes and trends, (iv) proposing a classification of relapsing retinoblastoma, (v) examining treatable/preventable disease-related or treatment-induced complications, and (vi) appraising new therapeutic targets and concepts, as well as liquid biopsy potentiality.
- Published
- 2019
12. Age-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trials
- Author
-
Ambros, I.M., Tonini, G.P., Gross, N., Mosseri, V., Pötschger, U., Beiske, K., Berbegall, A.P., Bénard, J., Bown, N., Caron, H., Combaret, V., Couturier, J., Defferrari, R., Delattre, O., Jeison, M., Kogner, P., Lunec, J., Marques, B., Martinsson, T., Mazzocco, K., Noguera, R., Schleiermacher, G., Valent, A., Van Roy, N., Villamon, E., Janousek, D., Pribill, I., Glogova, E., Attiyeh, E.F., Hogarty, M.D., Monclair, T., Holmes, K., Valteau-Couanet, D., Pearson ADJ, A.D.J., Castel, V., Tweddle, D.A., Park, J.R., Cohn, S., Ladenstein, R., Beck-Popovic, M., De Bernardi, B., Michon, J., and Ambros, P.F.
- Subjects
Neuroblastoma ,Tumor Genomics ,MYCN ,Doenças Genéticas - Abstract
BACKGROUND: Biology based treatment reduction, i.e. surgery alone also in case of not totally resected tumors, was advised in neuroblastoma patients with localized resectable disease without MYCN amplification. However, whether the genomic background of these tumors may influence outcome was unknown and therefore scrutinized in a meta-analysis comprising two prospective therapy studies and a ‘validation’ cohort. PATIENTS AND METHODS: Diagnostic samples were derived from 406 INSS stages 1/2A/2B tumors from three cohorts: LNESGI/II and COG. Genomic data were analyzed in two age groups (cut-off: 18 months) and quality controlled by the SIOPEN Biology Group. RESULTS: In both patient age groups stage 2 tumors led to similarly reduced event-free survival (5y-EFS: 83+3% versus 80+4%), but overall survival was only decreased in patients >18m (5y-OS: 97+1% versus 87+4%; p=0.001). In the latter age subgroup, only tumors with SCA led to relapses, with 11q loss as the strongest marker (5y-EFS: 40+15% versus 89+5%; p18m but not
- Published
- 2018
13. Validation of questionnaire-reported chest wall abnormalities with a telephone interview in Swiss childhood cancer survivors.
- Author
-
Kasteler, Rahel, Lichtensteiger, Christa, Schindera, Christina, Ansari, Marc, Kuehni, Claudia E., for the Swiss Pediatric Oncology Group (SPOG) Scientific Committee, Rössler, J., Ansari, M., Beck Popovic, M., Brazzola, P., Greiner, J., Niggli, F., Hengartner, H., Kuehni, C., Schilling, F., Scheinemann, K., von der Weid, N., Gerber, N., and Swiss Pediatric Oncology Group (SPOG) Scientific Committee
- Subjects
CENTRAL nervous system tumors ,CHILDHOOD cancer ,CANCER survivors ,TELEPHONE interviewing ,PHYSICIANS ,HUMAN abnormalities ,CHEST (Anatomy) ,RESEARCH evaluation ,INTERVIEWING ,RESEARCH funding - Abstract
Background: Chest wall abnormalities are a poorly studied complication after treatment for childhood cancer. Chest wall abnormalities are not well-described in the literature, and little is known on the impact on daily life of survivors.Methods: We investigated prevalence and risk factors of chest wall abnormalities in childhood cancer survivors in a nationwide, population-based cohort study (Swiss Childhood Cancer Survivor Study) with a questionnaire survey. We then interviewed a nested sample of survivors to validate types of chest wall abnormalities and understand their impact on the daily life of survivors.Results: Forty-eight of 2382 (95%CI 2-3%) survivors reported a chest wall abnormality. Risk factors were older age at cancer diagnosis (16-20 years; OR 2.5, 95%CI 1.0-6.1), lymphoma (OR 3.8, 95%CI 1.2-11.4), and central nervous system tumors (OR 9.5, 95%CI 3.0-30.1) as underlying disease, and treatment with thoracic radiotherapy (OR 2.0, 95%CI 1.0-4.2), surgery to the chest (OR 4.5, 95%CI 1.8-11.5), or chemotherapy (OR 2.9, 95%CI 1.0-8.1). The nature of the chest wall abnormalities varied and included thoracic wall deformities (30%), deformations of the spine (5%) or both (55%), and scars (10%). Chest wall abnormalities affected daily life in two thirds (13/20) of those who reported these problems and necessitated medical attention for 15 (75%) survivors.Conclusion: It is important that, during follow-up care, physicians pay attention to chest wall abnormalities, which are rare late effects of cancer treatment, but can considerably affect the well-being of cancer survivors. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
14. First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20 years of treatment
- Author
-
Munier, F.L., Mosimann, P., Puccinelli, F., Gaillard, M.C., Stathopoulos, C., Houghton, S., Bergin, C., and Beck-Popovic, M.
- Subjects
Aftercare ,Antineoplastic Combined Chemotherapy Protocols/administration & dosage ,Carboplatin/administration & dosage ,Child ,Child, Preschool ,Etoposide/administration & dosage ,Humans ,Infant ,Infusions, Intra-Arterial ,Infusions, Intravenous ,Melphalan/administration & dosage ,Retinal Neoplasms/drug therapy ,Retinoblastoma/drug therapy ,Retrospective Studies ,Salvage Therapy/methods ,Treatment Outcome ,Vision Disorders/prevention & control ,Child health (paediatrics) ,Neoplasia ,Retina ,Treatment Medical - Abstract
The introduction of intra-arterial chemotherapy (IAC) as salvage treatment has improved the prognosis for eye conservation in group D retinoblastoma. The aim of this study was to compare the outcomes of consecutive patients with advanced unilateral disease treated with either first-line intravenous chemotherapy (IVC) or first-line IAC. This is a retrospective mono-centric comparative review of consecutive patients. Sporadic unilateral retinoblastoma group D cases treated conservatively at Jules-Gonin Eye Hospital and CHUV between 1997 and 2014. From January 1997 to August 2008, IVC, combined with focal treatments, was the primary treatment approach. From September 2008 to October 2014, IAC replaced IVC as first-line therapy. 48 patients met the inclusion criteria, receiving only either IAC or IVC as primary treatment modality. Outcomes of 23 patients treated by IVC were compared with those of 25 treated by IAC; mean follow-up was 105.3 months (range 29.2-218.6) and 41.7 months (range 19.6-89.5), respectively. Treatment duration was significantly shorter in the IAC group (p
- Published
- 2017
15. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?
- Author
-
Delaloye, J., Merlani, G., Petignat, C., Wenger, A., Zaman, K., Monnerat, C., Matzinger, O., Beck Popovic, M., Vuichard, P., Ketterer, N., Tarr, P., Delaloye, J., Merlani, G., Petignat, C., Wenger, A., Zaman, K., Monnerat, C., Matzinger, O., Beck Popovic, M., Vuichard, P., Ketterer, N., and Tarr, P.
- Abstract
An increased frequency of nontyphoidal salmonellosis is well established in cancer patients, but it is unclear whether this represents increased susceptibility to exogenous infection or opportunistic, endogenous reactivation of asymptomatic carriage. In a retrospective study, a simple case definition was used to identify the probable presence of reactivation salmonellosis in five cancer patients between 1996 and 2002. Reactivation salmonellosis was defined as the development of nosocomial diarrhea >72h after admission and following the administration of antineoplastic chemotherapy in an HIV-seronegative cancer patient who was asymptomatic on admission, in the absence of epidemiological evidence of a nosocomial outbreak. Primary salmonellosis associated with unrecognized nosocomial transmission or community acquisition and an unusually prolonged incubation period could not entirely be ruled out. During the same time period, another opportunistic infection, Pneumocystis pneumonia, was diagnosed in six cancer patients. Presumably, asymptomatic intestinal Salmonella colonization was converted to invasive infection by chemotherapy-associated intestinal mucosal damage and altered innate immune mechanisms. According to published guidelines, stool specimens from patients hospitalized for longer than 72h should be rejected unless the patient is neutropenic or ≧65 years old with significant comorbidity. However, in this study neutropenia was present in only one patient, and four patients were <65 years old. Guidelines should thus be revised in order not to reject stool culture specimens from such patients. In cancer patients, nosocomial salmonellosis can occur as a chemotherapy-triggered opportunistic reactivation infection that may be similar in frequency to Pneumocystis pneumonia
- Published
- 2018
16. Treatment of Recurrent or Progressive Intraocular Retinoblastoma: Preliminary Results of A National Phase Ii Study of The Swiss Pediatric Oncology Group
- Author
-
Beck Popovic, M, Binaghi, S, Gaillard, MC, Diezi, M, Garcia, E, Houghton, S, Galley, MT, Cornu, M, Pampallona, S, and Munier, F
- Published
- 2014
17. Retinal toxicity following intra-vitreal injections of melphalan
- Author
-
Munier, F., primary, Gaillard, M.C., additional, Stathopoulos, C., additional, and Beck-Popovic, M., additional
- Published
- 2016
- Full Text
- View/download PDF
18. RISK FACTORS WITHIN THE EUROPEAN HIGH RISK NEUROBLASTOMA HR-NBL1/SIOPEN TRIAL
- Author
-
Ladenstein, R., Poetschger, U., Luksch, R., Brock, P., Castel, V., Yaniv, I., Papadakis, V., Laureys, G., Malis, J., Balwierz, W., Ruud, E., Kogner, P., Schroeder, H., Forjaz De Lacerda, A., Beck-Popovic, M., Bician, P., Garami, M., Trahair, T., Ambros, P., Holmes, K., Gaze, M., Pearson, A. D. J., and Valteau-Couanet, D.
- Published
- 2014
19. A Prospective Multicenter SPOG 2003 FN Study of Microbiologically Defined Infections in Pediatric Cancer Patients with Fever and Neutropenia
- Author
-
Agyeman P, Kontny U, Nadal D, Kurt Leibundgut, Niggli F, Simon A, Kronenberg A, Frei R, Escobar H, Kühne T, Beck-Popovic M, Bodmer N, and Ra, Ammann
- Subjects
570 Life sciences ,biology ,610 Medicine & health - Abstract
BACKGROUND: Fever and neutropenia (FN) often complicate anticancer treatment and can be caused by potentially fatal infections. Knowledge of pathogen distribution is paramount for optimal patient management. METHODS: Microbiologically defined infections (MDI) in pediatric cancer patients presenting with FN by nonmyeloablative chemotherapy enrolled in a prospective multi-center study were analyzed. Effectiveness of empiric antibiotic therapy in FN episodes with bacteremia was assessed taking into consideration recently published treatment guidelines for pediatric patients with FN. RESULTS: MDI were identified in a minority (22%) of pediatric cancer patients with FN. In patients with, compared to without MDI, fever (median, 5 [IQR 3-8] vs. 2 [IQR1-3] days, p < 0.001) and hospitalization (10 [6-14] vs. 5 [3-8] days, p < 0.001) lasted longer, transfer to the intensive care unit was more likely (13 of 95 [14%] vs. 7 of 346 [2.0%], p < 0.001), and antibiotics were given longer (10 [7-14] vs. 5 [4-7], p < 0.001). Empiric antibiotic therapy in FN episodes with bacteremia was highly effective if not only intrinsic and reported antimicrobial susceptibilities were considered but the purposeful omission of coverage for coagulase negative staphylococci and enterococci was also taken into account (81% [95%CI 68 - 90] vs. 96.6% [95%CI 87 - 99.4], p = 0.004) CONCLUSIONS: MDI were identified in a minority of FN episodes but they significantly affected management and the clinical course of pediatric cancer patients. Compliance with published guidelines was associated with effectiveness of empiric antibiotic therapy in FN episodes with bacteremia.
- Published
- 2014
- Full Text
- View/download PDF
20. Congenital tumors: imaging when life just begins
- Author
-
Alamo, L., Beck-Popovic, M., Gudinchet, F., and Meuli, R.
- Subjects
Pediatric oncology ,Prenatal diagnosis ,Fetal US ,Fetal MRI ,Neonatal imaging - Abstract
BACKGROUND: The technical developments of imaging methods over the last 2 decades are changing our knowledge of perinatal oncology. Fetal ultrasound is usually the first imaging method used and thus constitutes the reference prenatal study, but MRI seems to be an excellent complementary method for evaluating the fetus. The widespread use of both techniques has increased the diagnosis rates of congenital tumors. During pregnancy and after birth, an accurate knowledge of the possibilities and limits of the different imaging techniques available would improve the information obtainable, thus helping the medical team to make the most appropriate decisions about therapy and to inform the family about the prognosis. CONCLUSION: In this review article, we describe the main congenital neoplasms, their prognosis and their imaging characteristics with the different pre- and postnatal imaging methods available.
- Published
- 2011
21. Unlicensed and off-label drug use in a Swiss paediatric university hospital
- Author
-
Mario Gehri, André Pannatier, Frey P, Beck-Popovic M, Fanconi S, Stoetter H, Jacques Cotting, Tolsa Jf, and Di Paolo Er
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Pilot Projects ,Off-label use ,Marketing authorization ,Hospitals, University ,medicine ,Humans ,Prospective Studies ,Practice Patterns, Physicians' ,Medical prescription ,Child ,Prospective cohort study ,Drug Approval ,Drug Labeling ,Paediatric patients ,Pharmaceutical industry ,Child, Preschool ,Female ,Hospitals, Pediatric ,Infant ,Infant, Newborn ,Pharmaceutical Preparations ,Physician's Practice Patterns ,Switzerland ,business.industry ,General Medicine ,University hospital ,Family medicine ,Emergency medicine ,Healthcare settings ,business - Abstract
BACKGROUND: Many medicines used in newborns, infants, children and adolescents are not licensed ("unlicensed") or are prescribed outside the terms of the marketing authorization ("off-label"). Several studies have shown that this is a common practice in various healthcare settings in the USA, Europe and Australia, but data are scarce in Switzerland. OBJECTIVES: The aim of our prospective study was to determine the proportion of unlicensed or off-label prescriptions in paediatric patients. METHODS: This pilot study was conducted prospectively over a six month period in the department of paediatrics of a university hospital. RESULTS: Sixty patients aged from three days to 14 years were included in the study. A total of 483 prescriptions were written for the patients. More than half of all prescriptions (247; 51%) followed the terms of the marketing authorization. 114 (24%) were unlicensed and 122 (25%) off-label. All patients received at least one unlicensed or offlabel medicine. CONCLUSION: The use of unlicensed or off-label medicines to treat children was found to be common. Co-operation between the pharmaceutical industry, national regulatory authorities, clinical researchers, healthcare professionals and parents is required in order to ensure that children do not remain "therapeutic orphans".
- Published
- 2006
- Full Text
- View/download PDF
22. Pulmonary inflammatory myofibroblastic tumour after Hodgkin's lymphoma
- Author
-
Ilic, V., primary, Dunet, V., additional, Beck-Popovic, M., additional, and Boubaker, A., additional
- Published
- 2014
- Full Text
- View/download PDF
23. Intravitreal chemotherapy: Indications and results
- Author
-
MUNIER, F, primary, GAILLARD, MC, additional, BALMER, A, additional, and BECK-POPOVIC, M, additional
- Published
- 2013
- Full Text
- View/download PDF
24. The use of ruthenium plaque brachytherapy in retinoblastoma
- Author
-
ABOUZEID, H, primary, MOECKLI, R, additional, GAILLARD, MC, additional, BECK-POPOVIC, M, additional, PICCA, A, additional, ZOGRAFOS, L, additional, BALMER, A, additional, PAMPALLONA, S, additional, and MUNIER, F, additional
- Published
- 2009
- Full Text
- View/download PDF
25. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group
- Author
-
De Bernardi, B, primary, Mosseri, V, additional, Rubie, H, additional, Castel, V, additional, Foot, A, additional, Ladenstein, R, additional, Laureys, G, additional, Beck-Popovic, M, additional, de Lacerda, A F, additional, Pearson, A D J, additional, De Kraker, J, additional, Ambros, P F, additional, de Rycke, Y, additional, Conte, M, additional, Bruzzi, P, additional, and Michon, J, additional
- Published
- 2008
- Full Text
- View/download PDF
26. Nosocomial nontyphoidal salmonellosis after antineoplastic chemotherapy: reactivation of asymptomatic colonization?
- Author
-
Delaloye, J., Merlani, G., Petignat, C., Wenger, A., Zaman, K., Monnerat, C., Matzinger, O., Beck Popovic, M., Vuichard, P., Ketterer, N., Tarr, P., Delaloye, J., Merlani, G., Petignat, C., Wenger, A., Zaman, K., Monnerat, C., Matzinger, O., Beck Popovic, M., Vuichard, P., Ketterer, N., and Tarr, P.
- Abstract
An increased frequency of nontyphoidal salmonellosis is well established in cancer patients, but it is unclear whether this represents increased susceptibility to exogenous infection or opportunistic, endogenous reactivation of asymptomatic carriage. In a retrospective study, a simple case definition was used to identify the probable presence of reactivation salmonellosis in five cancer patients between 1996 and 2002. Reactivation salmonellosis was defined as the development of nosocomial diarrhea >72h after admission and following the administration of antineoplastic chemotherapy in an HIV-seronegative cancer patient who was asymptomatic on admission, in the absence of epidemiological evidence of a nosocomial outbreak. Primary salmonellosis associated with unrecognized nosocomial transmission or community acquisition and an unusually prolonged incubation period could not entirely be ruled out. During the same time period, another opportunistic infection, Pneumocystis pneumonia, was diagnosed in six cancer patients. Presumably, asymptomatic intestinal Salmonella colonization was converted to invasive infection by chemotherapy-associated intestinal mucosal damage and altered innate immune mechanisms. According to published guidelines, stool specimens from patients hospitalized for longer than 72h should be rejected unless the patient is neutropenic or ≧65 years old with significant comorbidity. However, in this study neutropenia was present in only one patient, and four patients were <65 years old. Guidelines should thus be revised in order not to reject stool culture specimens from such patients. In cancer patients, nosocomial salmonellosis can occur as a chemotherapy-triggered opportunistic reactivation infection that may be similar in frequency to Pneumocystis pneumonia
27. Low adherence to dietary recommendations in adult childhood cancer survivors
- Author
-
Grit Sommer, Jeanette Greiner, Kurt Leibundgut, Laura Wengenroth, Pierluigi Brazzola, Roland A. Ammann, Marc Ansari, T. Kuehne, N. X. von der Weid, Fabiën N. Belle, Johannes Rischewski, Maja Beck Popovic, M. Beck Popovic, R. Angst, Michael A. Grotzer, Heinz Hengartner, Murielle Bochud, Annette Weiss, Claudia E. Kuehni, Eva Bergstraesser, Felix Niggli, Swiss Paediatric Oncology Group (SPOG), Ammann, R., Angst, R., Ansari, M., Beck Popovic, M., Bergstraesser, E., Brazzola, P., Greiner, J., Grotzer, M., Hengartner, H., Kuehne, T., Leibundgut, K., Niggli, F., Rischewski, J., and von der Weid, N.
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pediatrics ,Cross-sectional study ,Population ,Disease ,Critical Care and Intensive Care Medicine ,Recommended Dietary Allowances ,Body Mass Index ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Cancer Survivors ,Case-Control Studies ,Cross-Sectional Studies ,Diet ,Female ,Humans ,Incidence ,Life Style ,Neoplasms/epidemiology ,Nutrition Assessment ,Patient Compliance ,Risk Factors ,Socioeconomic Factors ,Surveys and Questionnaires ,Switzerland/epidemiology ,Cardiovascular diseases ,Childhood cancer survivors ,Dietary recommendations ,Europe ,Swiss Childhood Cancer Registry ,Internal medicine ,Neoplasms ,medicine ,030212 general & internal medicine ,Young adult ,education ,610 Medicine & health ,education.field_of_study ,ddc:618 ,Nutrition and Dietetics ,business.industry ,Incidence (epidemiology) ,fungi ,Case-control study ,Institutional repository ,030220 oncology & carcinogenesis ,business ,Body mass index ,360 Social problems & social services ,Switzerland - Abstract
Background & aims Poor diet may increase the risk that childhood cancer survivors (CCS) will suffer from chronic disease. We compared adherence to national dietary recommendations between CCS, their siblings and the Swiss population, identified determinants of adherence, and assessed the association of adherence with cardiovascular disease (CVD) risk profiles. Methods As part of the Swiss Childhood Cancer Survivor Study (SCCSS), a questionnaire was sent to all Swiss resident CCS aged
- Published
- 2016
28. Childhood cancer and nuclear power plants in Switzerland: a census-based cohort study
- Author
-
Ben D, Spycher, Martin, Feller, Marcel, Zwahlen, Martin, Röösli, Nicolas X, von der Weid, Heinz, Hengartner, Matthias, Egger, Claudia E, Kuehni, M, Oris, Swiss Paediatric Oncology Group, Swiss National Cohort Study Group, Angst, R., Paulussen, M., Kuehne, T., Brazzola, P., Hirt, A., Leibundgut, K., Ozsahin, AH., Beck Popovic, M., von der Weid NX., Nobile Buetti, L., Rischewski, J., Caflisch, U., Greiner, J., Hengartner, H., Grotzer, M., Niggli, F., Gutzwiller, F., Bopp, M., Faeh, D., Egger, M., Clough-Gorr, K., Schmidlin, K., Spoerri, A., Sturdy, M., Zwahlen, M., Künzli, N., Paccaud, F., Oris, M., University of Zurich, and Kuehni, C E
- Subjects
Male ,Pediatrics ,Epidemiology ,030218 nuclear medicine & medical imaging ,Cohort Studies ,0302 clinical medicine ,Residence Characteristics ,Risk Factors ,Radiation, Ionizing ,Neoplasms ,Medicine ,Registries ,Child ,Leukemia, Radiation-Induced ,education.field_of_study ,Childhood Cancer Registry ,Geography ,Child Health ,Censuses ,General Medicine ,Environmental exposure ,Census ,Nuclear power ,3. Good health ,030220 oncology & carcinogenesis ,Child, Preschool ,Nuclear Power Plants ,Cohort ,leukaemia ,symbols ,Regression Analysis ,Female ,ionizing radiation ,Switzerland ,Cohort study ,Adolescent ,Air Pollutants, Radioactive/adverse effects ,Environmental Exposure/adverse effects ,Humans ,Infant ,Infant, Newborn ,Leukemia, Radiation-Induced/epidemiology ,Leukemia, Radiation-Induced/etiology ,Neoplasms/chemically induced ,Neoplasms/epidemiology ,Switzerland/epidemiology ,medicine.medical_specialty ,Population ,Childhood cancer ,610 Medicine & health ,population based ,03 medical and health sciences ,symbols.namesake ,Environmental health ,cancer ,cancer registry ,Poisson regression ,education ,business.industry ,Cancer ,Environmental Exposure ,medicine.disease ,Childhood ,Cancer registry ,10036 Medical Clinic ,Air Pollutants, Radioactive ,business ,Nuclear medicine ,2713 Epidemiology - Abstract
BACKGROUND: Previous studies on childhood cancer and nuclear power plants (NPPs) produced conflicting results. We used a cohort approach to examine whether residence near NPPs was associated with leukaemia or any childhood cancer in Switzerland. METHODS: We computed person-years at risk for children aged 0-15 years born in Switzerland from 1985 to 2009, based on the Swiss censuses 1990 and 2000 and identified cancer cases from the Swiss Childhood Cancer Registry. We geo-coded place of residence at birth and calculated incidence rate ratios (IRRs) with 95% confidence intervals (CIs) comparing the risk of cancer in children born 15 km away, using Poisson regression models. RESULTS: We included 2925 children diagnosed with cancer during 21 117 524 person-years of follow-up; 953 (32.6%) had leukaemia. Eight and 12 children diagnosed with leukaemia at ages 0-4 and 0-15 years, and 18 and 31 children diagnosed with any cancer were born 15 km away, the IRRs (95% CI) for leukaemia in 0-4 and 0-15 year olds were 1.20 (0.60-2.41) and 1.05 (0.60-1.86), respectively. For any cancer, corresponding IRRs were 0.97 (0.61-1.54) and 0.89 (0.63-1.27). There was no evidence of a dose-response relationship with distance (P > 0.30). Results were similar for residence at diagnosis and at birth, and when adjusted for potential confounders. Results from sensitivity analyses were consistent with main results. CONCLUSIONS: This nationwide cohort study found little evidence of an association between residence near NPPs and the risk of leukaemia or any childhood cancer.
- Published
- 2011
- Full Text
- View/download PDF
29. Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism
- Author
-
Maja Popovic, Ermindo R. Di Paolo, Katharina Rentsch, Rita Turello, University of Zurich, and Beck Popovic, M
- Subjects
Antimetabolites, Antineoplastic ,medicine.medical_specialty ,2720 Hematology ,610 Medicine & health ,Reductase ,Pharmacology ,Lymphoma, T-Cell ,Pediatrics ,Gastroenterology ,Polymorphism (computer science) ,Internal medicine ,540 Chemistry ,Carboxypeptidase-G2 ,medicine ,Humans ,Mthfr c677t ,2735 Pediatrics, Perinatology and Child Health ,Child ,Methylenetetrahydrofolate Reductase (NADPH2) ,10038 Institute of Clinical Chemistry ,Polymorphism, Genetic ,biology ,business.industry ,Homozygote ,Hematology ,Acute Kidney Injury ,medicine.disease ,Perinatology ,Lymphoma ,and Child Health ,Methotrexate ,Oncology ,Methylenetetrahydrofolate reductase ,Pediatrics, Perinatology and Child Health ,Toxicity ,biology.protein ,2730 Oncology ,Female ,business ,medicine.drug - Abstract
We report the case of an 11-year-old female treated for mediastinal T-cell lymphoma who presented renal failure following the second cycle of high-dose methotrexate (HDMTX). Because of life threatening plasma methotrexate (MTX) levels, carboxypeptidase G2 (CPDG2) was administered resulting in a dramatic decrease within 1 hr. The patient recovered from renal failure and no other side effects were observed. Homozygosity for the methylentetrahydrofolate reductase (MTHFR) C677T polymorphism diagnosed by molecular genetic analysis was the only explanation for this toxicity.
- Published
- 2008
- Full Text
- View/download PDF
30. Domestic Radon Exposure and Risk of Childhood Cancer: A Prospective Census-Based Cohort Study
- Author
-
Hauri, D., Spycher, B., Huss, A., Zimmermann, F., Grotzer, M., von der Weid, N., Weber, D., Spoerri, A., Kuehni, C.E., Röösli, M., Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Risk Assessment of Toxic and Immunomodulatory Agents, Dep IRAS, Swiss National Cohort, Swiss Paediatric Oncology Group (SPOG), Gutzwiller, F., Bopp, M., Egger, M., Spoerri, A., Zwahlen, M., Künzli, N., Paccaud, F., Oris, M., Ammann, R., Angst, R., Ansari, M., Beck Popovic, M., Bergstraesser, E., Brazzola, P., Greiner, J., Grotzer, M., Hengartner, H., Kuehne, T., Leibundgut, K., Niggli, F., Rischewski, J., von der Weid, N., University of Zurich, and Röösli, Martin
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Health, Toxicology and Mutagenesis ,Childhood cancer ,chemistry.chemical_element ,Radon ,610 Medicine & health ,Ionizing radiation ,Radon exposure ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,360 Social problems & social services ,Neoplasms ,Environmental health ,2307 Health, Toxicology and Mutagenesis ,Humans ,Medicine ,Prospective Studies ,030212 general & internal medicine ,Child ,Prospective cohort study ,business.industry ,Research ,Public Health, Environmental and Occupational Health ,Censuses ,Environmental Exposure ,Environmental exposure ,2739 Public Health, Environmental and Occupational Health ,Census ,3. Good health ,chemistry ,Air Pollutants, Radioactive ,10036 Medical Clinic ,Child, Preschool ,030220 oncology & carcinogenesis ,Air Pollutants, Radioactive/adverse effects ,Female ,Neoplasms/epidemiology ,Radon/adverse effects ,business ,Cohort study - Abstract
Background: In contrast with established evidence linking high doses of ionizing radiation with childhood cancer, research on low-dose ionizing radiation and childhood cancer has produced inconsistent results. Objective: We investigated the association between domestic radon exposure and childhood cancers, particularly leukemia and central nervous system (CNS) tumors. Methods: We conducted a nationwide census-based cohort study including all children < 16 years of age living in Switzerland on 5 December 2000, the date of the 2000 census. Follow-up lasted until the date of diagnosis, death, emigration, a child’s 16th birthday, or 31 December 2008. Domestic radon levels were estimated for each individual home address using a model developed and validated based on approximately 45,000 measurements taken throughout Switzerland. Data were analyzed with Cox proportional hazard models adjusted for child age, child sex, birth order, parents’ socioeconomic status, environmental gamma radiation, and period effects. Results: In total, 997 childhood cancer cases were included in the study. Compared with children exposed to a radon concentration below the median (< 77.7 Bq/m3), adjusted hazard ratios for children with exposure ≥ the 90th percentile (≥ 139.9 Bq/m3) were 0.93 (95% CI: 0.74, 1.16) for all cancers, 0.95 (95% CI: 0.63, 1.43) for all leukemias, 0.90 (95% CI: 0.56, 1.43) for acute lymphoblastic leukemia, and 1.05 (95% CI: 0.68, 1.61) for CNS tumors. Conclusions: We did not find evidence that domestic radon exposure is associated with childhood cancer, despite relatively high radon levels in Switzerland. Citation: Hauri D, Spycher B, Huss A, Zimmermann F, Grotzer M, von der Weid N, Weber D, Spoerri A, Kuehni C, Röösli M, for the Swiss National Cohort and the Swiss Paediatric Oncology Group (SPOG). 2013. Domestic radon exposure and risk of childhood cancer: a prospective census-based cohort study. Environ Health Perspect 121:1239–1244; http://dx.doi.org/10.1289/ehp.1306500
- Published
- 2013
- Full Text
- View/download PDF
31. Physical performance limitations in adolescent and adult survivors of childhood cancer and their siblings
- Author
-
Corina S, Rueegg, Gisela, Michel, Laura, Wengenroth, Nicolas X, von der Weid, Eva, Bergstraesser, Claudia E, Kuehni, N, von der Weid, University of Zurich, Swiss Paediatric Oncology Group (SPOG), Ammann, R., Angst, R., Beck Popovic, M., Bergstraesser, E., Brazzola, P., Caflisch, U., Greiner, J., Grotzer, M., Hengartner, H., Kühne, T., Leibundgut, K., Niggli, F., Nobile Buetti, L., Ozsahin, H., Paulussen, M., Rischewski, J., and von der Weid, N.
- Subjects
Male ,Pediatrics ,Activities of daily living ,Anatomy and Physiology ,Epidemiology ,medicine.medical_treatment ,Cancer Treatment ,Logistic regression ,Cohort Studies ,0302 clinical medicine ,Neoplasms ,Surveys and Questionnaires ,Activities of Daily Living ,Medicine ,030212 general & internal medicine ,Survivors ,Young adult ,Child ,Pediatric Epidemiology ,Childhood Cancer Registry ,Multidisciplinary ,Statistics ,Child Health ,Socioeconomic Aspects of Health ,3. Good health ,Oncology ,030220 oncology & carcinogenesis ,Observational Studies ,Female ,Public Health ,Cancer Epidemiology ,Sports ,Research Article ,Adult ,medicine.medical_specialty ,Adolescent ,Clinical Research Design ,Science ,610 Medicine & health ,1100 General Agricultural and Biological Sciences ,Childhood Cancer Survivor Study ,Motor Activity ,Biostatistics ,03 medical and health sciences ,Young Adult ,Adolescent Medicine ,1300 General Biochemistry, Genetics and Molecular Biology ,Humans ,Pediatric Hematology ,Statistical Methods ,Sports and Exercise Medicine ,1000 Multidisciplinary ,Survey Research ,business.industry ,Siblings ,Odds ratio ,Radiation therapy ,Neoplasms/complications ,Neoplasms/physiopathology ,Questionnaires ,10036 Medical Clinic ,Physical performance ,Pediatric Oncology ,Physiotherapy and Rehabilitation ,Preventive Medicine ,business ,Mathematics - Abstract
PurposeThis study investigates physical performance limitations for sports and daily activities in recently diagnosed childhood cancer survivors and siblings.MethodsThe Swiss Childhood Cancer Survivor Study sent a questionnaire to all survivors (≥ 16 years) registered in the Swiss Childhood Cancer Registry, who survived >5 years and were diagnosed 1976-2003 aged ResultsThe sample included 1038 survivors and 534 siblings. Overall, 96 survivors (9.5%) and 7 siblings (1.1%) reported a limitation in sports (Odds ratio 5.5, 95%CI 2.9-10.4, pConclusionSurvivors of childhood cancer, even those diagnosed recently and treated with modern protocols, remain at high risk for physical performance limitations. Treatment and follow-up care should include tailored interventions to mitigate these late effects in high-risk patients.
- Published
- 2012
- Full Text
- View/download PDF
32. Daily Physical Activities and Sports in Adult Survivors of Childhood Cancer and Healthy Controls: A Population-Based Questionnaire Survey
- Author
-
Rueegg, Corina S., von der Weid, Nicolas X., Rebholz, Cornelia E., Michel, Gisela, Zwahlen, Marcel, Grotzer, Michael, Kuehni, Claudia E., Swiss Paediatric Oncology Group, SPOG, Swiss Paediatric Oncology Group (SPOG), Ammann, R., Angst, R., Beck Popovic, M., Brazzola, P., Caflisch, U., Greiner, J., Grotzer, M., Hengartner, H., Kühne, T., Leibundgut, K., Niggli, F., Nobile Buetti, L., Ozsahin, H., Paulussen, M., Rischewski, J., von der Weid, N., and University of Zurich
- Subjects
Gerontology ,Male ,Activities of daily living ,Epidemiology ,Life Course Epidemiology ,Logistic regression ,Pediatrics ,0302 clinical medicine ,Risk Factors ,Neoplasms ,Surveys and Questionnaires ,Clinical Epidemiology ,030212 general & internal medicine ,Survivors ,Young adult ,Pediatric Epidemiology ,education.field_of_study ,Childhood Cancer Registry ,Multidisciplinary ,Child Health ,Hematology ,Socioeconomic Aspects of Health ,3. Good health ,Oncology ,030220 oncology & carcinogenesis ,Medicine ,Female ,Public Health ,Behavioral and Social Aspects of Health ,Cancer Epidemiology ,Sports ,Research Article ,Adult ,Science ,Population ,610 Medicine & health ,Childhood Cancer Survivor Study ,1100 General Agricultural and Biological Sciences ,Motor Activity ,03 medical and health sciences ,Young Adult ,1300 General Biochemistry, Genetics and Molecular Biology ,medicine ,Case-Control Studies ,Health Surveys ,Humans ,Life Style ,Logistic Models ,Neoplasms/physiopathology ,Neoplasms/rehabilitation ,Questionnaires ,Pediatric Hematology ,Sports and Exercise Medicine ,education ,Biology ,1000 Multidisciplinary ,Population Biology ,business.industry ,Case-control study ,medicine.disease ,Obesity ,10036 Medical Clinic ,Pediatric Oncology ,Physiotherapy and Rehabilitation ,Preventive Medicine ,business - Abstract
BACKGROUND: Healthy lifestyle including sufficient physical activity may mitigate or prevent adverse long-term effects of childhood cancer. We described daily physical activities and sports in childhood cancer survivors and controls, and assessed determinants of both activity patterns. METHODOLOGY/PRINCIPAL FINDINGS: The Swiss Childhood Cancer Survivor Study is a questionnaire survey including all children diagnosed with cancer 1976-2003 at age 0-15 years, registered in the Swiss Childhood Cancer Registry, who survived ≥5 years and reached adulthood (≥20 years). Controls came from the population-based Swiss Health Survey. We compared the two populations and determined risk factors for both outcomes in separate multivariable logistic regression models. The sample included 1058 survivors and 5593 controls (response rates 78% and 66%). Sufficient daily physical activities were reported by 52% (n = 521) of survivors and 37% (n = 2069) of controls (p
- Published
- 2012
- Full Text
- View/download PDF
33. Health-related quality of life in long-term survivors of relapsed childhood acute lymphoblastic leukemia
- Author
-
Stefan Essig, Nicolas X von der Weid, Marie-Pierre F Strippoli, Cornelia E Rebholz, Gisela Michel, Corina S Rueegg, Felix K Niggli, Claudia E Kuehni, Swiss Pediatric Oncology Group (SPOG), Swiss Pediatric Oncology Group (SPOG), Ammann, R., Angst, R., Beck Popovic, M., Brazzola, P., Greiner, J., Hengartner, H., Kuehne, T., Leibundgut, K., Niggli, F., Nobile Buetti, L., Ozsahin, A., Rischewski, J., Grotzer, M., and von der Weid, N.
- Subjects
Male ,Pediatrics ,Non-Clinical Medicine ,Epidemiology ,Lymphoblastic Leukemia ,Hematologic Cancers and Related Disorders ,0302 clinical medicine ,Quality of life ,Recurrence ,Surveys and Questionnaires ,Reference population ,Survivors ,030212 general & internal medicine ,Child ,Pediatric Epidemiology ,education.field_of_study ,Multidisciplinary ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Acute Lymphoblastic Leukemia ,humanities ,3. Good health ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Medicine ,Female ,Public Health ,Adolescent ,Humans ,Infant ,Infant, Newborn ,Precursor Cell Lymphoblastic Leukemia-Lymphoma/psychology ,Quality of Life ,Questionnaires ,Survivors/psychology ,Switzerland ,Cancer Epidemiology ,Research Article ,medicine.medical_specialty ,Relapsed Childhood Acute Lymphoblastic Leukemia ,Science ,Population ,Childhood Cancer Survivor Study ,03 medical and health sciences ,Leukemias ,medicine ,education ,Health related quality of life ,Health Care Policy ,business.industry ,Cancers and Neoplasms ,Long-Term Care ,Mental health ,Pediatric Oncology ,Preventive Medicine ,business - Abstract
BackgroundRelapses occur in about 20% of children with acute lymphoblastic leukemia (ALL). Approximately one-third of these children can be cured. Their risk for late effects is high because of intensified treatment, but their health-related quality of life (HRQOL) was largely unmeasured. Our aim was to compare HRQOL of ALL survivors with the general population, and of relapsed with non-relapsed ALL survivors.Methodology/principal findingsAs part of the Swiss Childhood Cancer Survivor Study (SCCSS) we sent a questionnaire to all ALL survivors in Switzerland who had been diagnosed between 1976-2003 at age Conclusion/significanceCompared to population norms, ALL survivors reported good HRQOL, even after a relapse. However, relapsed ALL survivors reported poorer general health than non-relapsed. Therefore, we encourage specialists to screen for poor general health in survivors after a relapse and, when appropriate, specifically seek and treat underlying late effects. This will help to improve patients' HRQOL.
- Published
- 2012
- Full Text
- View/download PDF
34. Anti-MAPK Targeted Therapy for Ameloblastoma: Case Report with a Systematic Review.
- Author
-
Raemy A, May L, Sala N, Diezi M, Beck-Popovic M, and Broome M
- Abstract
Ameloblastoma, a benign yet aggressive odontogenic tumor known for its recurrence and the severe morbidity from radical surgeries, may benefit from advancements in targeted therapy. We present a case of a 15-year-old girl with ameloblastoma successfully treated with targeted therapy and review the literature with this question: Is anti-MAPK targeted therapy safe and effective for treating ameloblastoma? This systematic review was registered in PROSPERO, adhered to PRISMA guidelines, and searched multiple databases up to December 2023, identifying 13 relevant studies out of 647 records, covering 23 patients treated with MAPK inhibitor therapies. The results were promising as nearly all patients showed a positive treatment response, with four achieving complete radiological remission and others showing substantial reductions in primary, recurrent, and metastatic ameloblastoma sizes. Side effects were mostly mild to moderate. This study presents anti-MAPK therapy as a significant shift from invasive surgical treatments, potentially enhancing life quality and clinical outcomes by offering a less invasive yet effective treatment alternative. This approach could signify a breakthrough in managing this challenging tumor, emphasizing the need for further research into molecular-targeted therapies., Competing Interests: The authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
35. MR Imaging of Adverse Effects and Ocular Growth Decline after Selective Intra-Arterial Chemotherapy for Retinoblastoma.
- Author
-
de Bloeme CM, van Elst S, Galluzzi P, Jansen RW, de Haan J, Göricke S, Moll AC, Bot JCJ, Munier FL, Beck-Popovic M, Puccinelli F, Aerts I, Hadjistilianou T, Sirin S, Koob M, Brisse HJ, Cardoen L, Maeder P, de Jong MC, and de Graaf P
- Abstract
This retrospective multicenter study examines therapy-induced orbital and ocular MRI findings in retinoblastoma patients following selective intra-arterial chemotherapy (SIAC) and quantifies the impact of SIAC on ocular and optic nerve growth. Patients were selected based on medical chart review, with inclusion criteria requiring the availability of posttreatment MR imaging encompassing T2-weighted and T1-weighted images (pre- and post-intravenous gadolinium administration). Qualitative features and quantitative measurements were independently scored by experienced radiologists, with deep learning segmentation aiding total eye volume assessment. Eyes were categorized into three groups: eyes receiving SIAC (Rb-SIAC), eyes treated with other eye-saving methods (Rb-control), and healthy eyes. The most prevalent adverse effects post-SIAC were inflammatory and vascular features, with therapy-induced contrast enhancement observed in the intraorbital optic nerve segment in 6% of patients. Quantitative analysis revealed significant growth arrest in Rb-SIAC eyes, particularly when treatment commenced ≤ 12 months of age. Optic nerve atrophy was a significant complication in Rb-SIAC eyes. In conclusion, this study highlights the vascular and inflammatory adverse effects observed post-SIAC in retinoblastoma patients and demonstrates a negative impact on eye and optic nerve growth, particularly in children treated ≤ 12 months of age, providing crucial insights for clinical management and future research.
- Published
- 2024
- Full Text
- View/download PDF
36. When the second comes first- rhabdomyosarcoma preceding heritable retinoblastoma- a case report.
- Author
-
Tripathy D, Moulin A, Bijon J, Gengler C, Beck-Popovic M, Munier FL, and Stathopoulos C
- Subjects
- Child, Humans, Mutation, Twins, Monozygotic, Neoplasms, Second Primary diagnosis, Neoplasms, Second Primary genetics, Retinal Neoplasms diagnosis, Retinal Neoplasms genetics, Retinal Neoplasms pathology, Retinoblastoma diagnosis, Retinoblastoma genetics, Retinoblastoma pathology, Rhabdomyosarcoma diagnosis, Rhabdomyosarcoma genetics
- Abstract
Background: Retinoblastoma (rb) is the most frequent intraocular tumor, accounting for 3% of all childhood cancers. Heritable rb survivors are germline carriers for an RB1 mutation and have a lifelong risk to develop non-ocular second primary tumors (SPTs) involving multiple other organs like the bones, soft tissues, or skin. These SPTs usually become manifest several years succeeding the diagnosis of rb. In our instance, however, a non-ocular SPT presented prior to the diagnosis of heritable rb., Case Presentation: We report a rare case of a monozygotic twin who presented with primary rhabdomyosarcoma (RMS) preceding the manifestation of heritable rb. The rb was diagnosed when the child developed strabismus while already on therapy for the RMS. The child underwent therapy for both as per defined treatment protocols. The rb regressed well on treatment, but the RMS relapsed and the child developed multiple refractory metastatic foci and succumbed to his disease., Conclusions: Non-ocular SPTs like sarcomas are usually known to manifest in heritable rb survivors with a lag of two to three decades (earlier if exposure to radiation is present) from the presentation of the rb. However, in our case, this seemed to be reversed with the RMS being manifest at an unusual early age and the rb being diagnosed at a later point in time., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. Risk factors for overweight and obesity after childhood acute lymphoblastic leukemia in North America and Switzerland: A comparison of two cohort studies.
- Author
-
Belle FN, Schindera C, Ansari M, Armstrong GT, Beck-Popovic M, Howell R, Leisenring WM, Meacham LR, Rössler J, Spycher BD, Tonorezos E, von der Weid NX, Yasui Y, Oeffinger KC, and Kuehni CE
- Subjects
- Adult, Child, Male, Humans, Middle Aged, Switzerland epidemiology, Obesity epidemiology, Obesity complications, Cohort Studies, Risk Factors, North America epidemiology, Overweight epidemiology, Overweight complications, Precursor Cell Lymphoblastic Leukemia-Lymphoma etiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications
- Abstract
Background: After childhood acute lymphoblastic leukemia (ALL), sequelae include overweight and obesity, yet with conflicting evidence. We compared the prevalence of overweight and obesity between ≥5-year ALL survivors from the North American Childhood Cancer Survivor Study (CCSS) and the Swiss Childhood Cancer Survivor Study (SCCSS) and described risk factors., Methods: We included adult childhood ALL survivors diagnosed between 1976 and 1999. We matched CCSS participants (3:1) to SCCSS participants by sex and attained age. We calculated body mass index (BMI) from self-reported height and weight for 1287 CCSS and 429 SCCSS participants; we then compared those with siblings (2034) in North America and Switzerland (678) siblings. We assessed risk factors for overweight (BMI 25-29.9 kg/m
2 ) and obesity (≥30 kg/m2 ) using multinomial regression., Results: We found overweight and obesity significantly more common among survivors in North America when compared with survivors in Switzerland [overweight: 30%, 95% confidence interval (CI): 27-32 vs. 24%, 21-29; obesity: 29%, 27-32 vs. 7%, 5-10] and siblings (overweight: 30%, 27-32 vs. 25%, 22-29; obesity: 24%, 22-26 vs. 6%, 4-8). Survivors in North America [odds ratio (OR) = 1.24, 1.01-1.53] and Switzerland (1.27, 0.74-2.21) were slightly more often obese than siblings. Among survivors, risk factors for obesity included residency in North America (5.8, 3.7-9.0); male (1.7, 1.3-2.3); attained age (≥45 years: 5.1, 2.4-10.8); Non-Hispanic Black (3.4, 1.6-7.0); low household income (2.3, 1.4-3.5); young age at diagnosis (1.6, 1.1-2.2). Cranial radiotherapy ≥18 Gray was only a risk factor for overweight (1.4, 1.0-1.8); steroids were not associated with overweight or obesity. Interaction tests found no evidence of difference in risk factors between cohorts., Conclusions: Although treatment-related risk for overweight and obesity were similar between regions, higher prevalence among survivors in North America identifies important sociodemographic drivers for informing health policy and targeted intervention trials., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)- Published
- 2023
- Full Text
- View/download PDF
38. CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ( 123/131 I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors.
- Author
-
Grand-Guillaume J, Mansi R, Gaonkar RH, Zanger S, Fani M, Eugster PJ, Beck Popovic M, Grouzmann E, and Abid K
- Subjects
- Humans, Animals, Mice, Histone Deacetylase Inhibitors pharmacology, Histone Deacetylase Inhibitors therapeutic use, 3-Iodobenzylguanidine pharmacology, 3-Iodobenzylguanidine therapeutic use, Phosphatidylinositol 3-Kinases, Precision Medicine, Neuroendocrine Tumors, Neuroblastoma diagnostic imaging, Neuroblastoma drug therapy
- Abstract
Background: Neuroblastoma (NB) and pheochromocytoma/paraganglioma (PHEO/PGL) are neuroendocrine tumors. Imaging of these neoplasms is performed by scintigraphy after injection of radiolabeled meta-iodobenzylguanidine (mIBG), a norepinephrine analog taken up by tumoral cells through monoamine transporters. The pharmacological induction of these transporters is a promising approach to improve the imaging and therapy (theranostics) of these tumors., Methods: Transporters involved in mIBG internalization were identified by using transfected Human Embryonic Kidney (HEK) cells. Histone deacetylase inhibitors (HDACi) and inhibitors of the PI3K/AKT/mTOR pathway were tested in cell lines to study their effect on mIBG internalization. Studies in xenografted mice were performed to assess the effect of the most promising HDACi on
123 I-mIBG uptake., Results: Transfected HEK cells demonstrated that the norepinephrine and dopamine transporter (NET and DAT) avidly internalizes mIBG. Sodium-4-phenylbutyrate (an HDACi), CUDC-907 (a dual HDACi and PI3K inhibitor), BGT226 (a PI3K inhibitor) and VS-5584 and rapamycin (two inhibitors of mTOR) increased mIBG internalization in a neuroblastoma cell line (IGR-NB8) by 2.9-, 2.1-, 2.5-, 1.5- and 1.3-fold, respectively, compared with untreated cells. CUDC-907 also increased mIBG internalization in two other NB cell lines and in one PHEO cell line. We demonstrated that mIBG internalization occurs primarily through the NET. In xenografted mice with IGR-NB8 cells, oral treatment with 5 mg/kg of CUDC-907 increased the tumor uptake of123 I-mIBG by 2.3- and 1.9-fold at 4 and 24 h post-injection, respectively, compared to the untreated group., Conclusions: Upregulation of the NET by CUDC-907 lead to a better internalization of mIBG in vitro and in vivo., (© 2023. BioMed Central Ltd., part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
39. Low number of neurosecretory vesicles in neuroblastoma impairs massive catecholamine release and prevents hypertension.
- Author
-
Mühlethaler-Mottet A, Uccella S, Marchiori D, La Rosa S, Daraspe J, Balmas Bourloud K, Beck Popovic M, Eugster PJ, Grouzmann E, and Abid K
- Subjects
- Child, Humans, Catechol O-Methyltransferase analysis, Metanephrine analysis, Metanephrine metabolism, Biomarkers, Pheochromocytoma metabolism, Adrenal Gland Neoplasms diagnosis, Paraganglioma, Neuroblastoma, Hypertension
- Abstract
Introduction: Neuroblastoma (NB) is a pediatric cancer of the developing sympathetic nervous system. It produces and releases metanephrines, which are used as biomarkers for diagnosis in plasma and urine. However, plasma catecholamine concentrations remain generally normal in children with NB. Thus, unlike pheochromocytoma and paraganglioma (PHEO/PGL), two other non-epithelial neuroendocrine tumors, hypertension is not part of the usual clinical picture of patients with NB. This suggests that the mode of production and secretion of catecholamines and metanephrines in NB is different from that in PHEO/PGL, but little is known about these discrepancies. Here we aim to provide a detailed comparison of the biosynthesis, metabolism and storage of catecholamines and metanephrines between patients with NB and PHEO., Method: Catecholamines and metanephrines were quantified in NB and PHEO/PGL patients from plasma and tumor tissues by ultra-high pressure liquid chromatography tandem mass spectrometry. Electron microscopy was used to quantify neurosecretory vesicles within cells derived from PHEO tumor biopsies, NB-PDX and NB cell lines. Chromaffin markers were detected by qPCR, IHC and/or immunoblotting., Results: Plasma levels of metanephrines were comparable between NB and PHEO patients, while catecholamines were 3.5-fold lower in NB vs PHEO affected individuals. However, we observed that intratumoral concentrations of metanephrines and catecholamines measured in NB were several orders of magnitude lower than in PHEO. Cellular and molecular analyses revealed that NB cell lines, primary cells dissociated from human tumor biopsies as well as cells from patient-derived xenograft tumors (NB-PDX) stored a very low amount of intracellular catecholamines, and contained only rare neurosecretory vesicles relative to PHEO cells. In addition, primary NB expressed reduced levels of numerous chromaffin markers, as compared to PHEO/PGL, except catechol O-methyltransferase and monoamine oxidase A. Furthermore, functional assays through induction of chromaffin differentiation of the IMR32 NB cell line with Bt2cAMP led to an increase of neurosecretory vesicles able to secrete catecholamines after KCl or nicotine stimulation., Conclusion: The low amount of neurosecretory vesicles in NB cytoplasm prevents catecholamine storage and lead to their rapid transformation by catechol O-methyltransferase into metanephrines that diffuse in blood. Hence, in contrast to PHEO/PGL, catecholamines are not secreted massively in the blood, which explains why systemic hypertension is not observed in most patients with NB., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Mühlethaler-Mottet, Uccella, Marchiori, La Rosa, Daraspe, Balmas Bourloud, Beck Popovic, Eugster, Grouzmann and Abid.)
- Published
- 2022
- Full Text
- View/download PDF
40. Presenting features of neuroblastoma with spinal canal invasion. A prospective study of the International Society of Pediatric Oncology Europe - Neuroblastoma (SIOPEN).
- Author
-
Sorrentino S, Ash S, Haupt R, Plantaz D, Schiff I, Hero B, Simon T, Kachanov D, Shamanskaya T, Kraal K, Littooij A, Wieczoreck A, Balwierz W, Laureys G, Trager C, Sertorio F, Erminio G, Fragola M, Beck Popovic M, De Bernardi B, and Trahair T
- Abstract
Introduction: Between 5 and 15% of children with neuroblastoma (NB) present with or develop spinal canal invasion (SCI). The majority of these children have symptoms of epidural compression of spinal cord and/or spinal nerves. Treatment of NB-SCI is considered an emergency but its modalities are not yet well-established. Independently of treatment, NB-SCI may result in significant long-term disabilities. We report on the first prospective study of NB-SCI focused on presenting characteristics of both symptomatic and asymptomatic patients and correlation between SCI-related symptoms and imaging features., Materials and Methods: This SIOPEN prospective NB-SCI study opened in June 2014. Patient data including SCI symptoms evaluated by standardized measures and spinal cord imaging studies were collected for each patient. For the purpose of this study data entry was locked on July 2021., Results: Of the 208 NB-SCI patients registered, 196 were evaluable for this analysis of whom 67% were symptomatic and 33% asymptomatic. Median age was 11 months. The thorax was the commonest primary tumor site. The median intervals between initial symptoms and diagnosis and between first medical visit and diagnosis were 14 and 3 days, respectively. The was no statistical difference in frequency of presenting characteristics between symptomatic and asymptomatic patients. Presenting features of NB-SCI patients differed from other NBs for older median age, prevalence of thoracic vs. abdominal primary site, prevalence of localized vs. metastatic disease and lower incidence of MYCN gene amplification. The most common SCI features were motor deficit in the younger and pain in the older patients that correlated on imaging with both transverse and longitudinal extent but not with the level of intraspinal tumor. Spinal cord T2-hyperintensity was more frequently detected in symptomatic patients (not significant)., Conclusion: This prospective study confirms that children with NB-SCI differ from NBs without SCI. Compared to previous studies, it provides more detailed information regarding presenting symptoms, time intervals between SCI symptoms, medical visit and diagnosis, and correlations between symptoms and imaging features., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Sorrentino, Ash, Haupt, Plantaz, Schiff, Hero, Simon, Kachanov, Shamanskaya, Kraal, Littooij, Wieczoreck, Balwierz, Laureys, Trager, Sertorio, Erminio, Fragola, Beck Popovic, De Bernardi and Trahair.)
- Published
- 2022
- Full Text
- View/download PDF
41. Neuroblastic Tumors of the Adrenal Gland in Elderly Patients: A Case Report and Review of the Literature.
- Author
-
Deslarzes P, Djafarrian R, Matter M, La Rosa S, Gengler C, Beck-Popovic M, and Zingg T
- Abstract
Background: Neuroblastic neoplasms (NN) include ganglioneuromas (GN), ganglioneuroblastomas (GNB), and neuroblastomas (NB). They generally arise in childhood from primitive sympathetic ganglion cells. Their incidence in adults, especially among elderly, is extremely low., Case Presentation: This is the case of a 74-year-old woman with history of abdominal pain, weakness and night sweating since several months. Blood pressure was normal. CT-scan showed a 10 cm left adrenal mass, without other pathologic findings. An open left-sided adrenalectomy was performed. Recovery was uneventful with hospital length of stay of 8 days. Based on morphological, immunohistochemical, and molecular features the diagnosis was a nodular GNB. A positron emission tomography (PET) performed 6 weeks after the resection did not show any residual tumor or distant metastases. The patient was followed-up with annual clinical and radiological exams., Conclusion: This case presentation, associated with a review of the literature, illustrates the importance to include NN in the preoperative differential diagnosis of adrenal tumors in adults and highlights the need for multidisciplinary patient work-up and management., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Deslarzes, Djafarrian, Matter, La Rosa, Gengler, Beck-Popovic and Zingg.)
- Published
- 2022
- Full Text
- View/download PDF
42. Current Indications of Secondary Enucleation in Retinoblastoma Management: A Position Paper on Behalf of the European Retinoblastoma Group (EURbG).
- Author
-
Stathopoulos C, Lumbroso-Le Rouic L, Moll AC, Parulekar M, Maeder P, Doz F, Jenkinson H, Beck Popovic M, Chantada G, and Munier FL
- Abstract
Secondary enucleation (SE) puts an irreversible end to eye-preserving therapies, whenever their prolongation is expected to violate the presumed state of metastatic grace. At present, it must be acknowledged that clear criteria for SE are missing, leading to empiric and subjective indications commonly related to disease progression or relapse, disease persistence masking the optic nerve head or treatment-related complications obscuring the fundus view. This absence of evidence-based consensus regarding SE is explained by the continuously moving frontiers of the conservative management as a result of diagnostic and therapeutic advances, as well as by the lack of studies sufficiently powered to accurately stratify the risk of metastasis in conservatively treated patients. In this position paper of the European Retinoblastoma Group (EURbG), we give an overview of the progressive shift in the indications for SE over the past decades and propose guidelines to assist decision-making with respect to when SE becomes imperative or recommended, with corresponding absolute and relative SE indications. Further studies and validation of biologic markers correlated with the risk of metastasis are expected to set more precisely the frontiers of conservative management and thus consensual criteria for SE in the future.
- Published
- 2021
- Full Text
- View/download PDF
43. Immune deficiency, autoimmune disease and intellectual disability: A pleiotropic disorder caused by biallelic variants in the TPP2 gene.
- Author
-
Atallah I, Quinodoz M, Campos-Xavier B, Peter VG, Fouriki A, Bonvin C, Bottani A, Kumps C, Angelini F, Bellutti Enders F, Christen-Zaech S, Rizzi M, Renella R, Beck-Popovic M, Poloni C, Frossard V, Blouin JL, Rivolta C, Riccio O, Candotti F, Hofer M, Unger S, and Superti-Furga A
- Subjects
- Adult, Child, Child, Preschool, Exons genetics, Female, Humans, Male, Young Adult, Aminopeptidases genetics, Autoimmune Diseases genetics, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases genetics, Frameshift Mutation genetics, Immunologic Deficiency Syndromes genetics, Serine Endopeptidases genetics
- Abstract
Four individuals from two families presented with a multisystemic condition of suspected genetic origin that was diagnosed only after genome analysis. The main phenotypic features were immune system dysregulation (severe immunodeficiency with autoimmunity) and intellectual disability. The four individuals were found to be homozygous for a 4.4 Kb deletion removing exons 20-23 (NM_003291.4) of the TPP2 gene, predicting a frameshift with premature termination of the protein. The deletion was located on a shared chromosome 13 haplotype indicating a Swiss founder mutation. Tripeptidyl peptidase 2 (TPP2) is a protease involved in HLA/antigen complex processing and amino acid homeostasis. Biallelic variants in TPP2 have been described in 10 individuals with variable features including immune deficiency, autoimmune cytopenias, and intellectual disability or chronic sterile brain inflammation mimicking multiple sclerosis. Our observations further delineate this severe condition not yet included in the OMIM catalog. Timely recognition of TPP2 deficiency is crucial since (1) immune surveillance is needed and hematopoietic stem cell transplantation may be necessary, and (2) for provision of genetic counselling. Additionally, enzyme replacement therapy, as already established for TPP1 deficiency, might be an option in the future., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
44. Dietary Intake and Diet Quality of Adult Survivors of Childhood Cancer and the General Population: Results from the SCCSS-Nutrition Study.
- Author
-
Belle FN, Chatelan A, Kasteler R, Mader L, Guessous I, Beck-Popovic M, Ansari M, Kuehni CE, and Bochud M
- Subjects
- Adult, Diet methods, Diet, Healthy, Dietary Fiber administration & dosage, Eating, Female, Fruit, Humans, Male, Middle Aged, Neoplasms therapy, Nutrition Surveys methods, Nutritional Status, Sodium, Dietary administration & dosage, Switzerland epidemiology, Vegetables, Young Adult, Cancer Survivors, Diet statistics & numerical data, Energy Intake
- Abstract
Childhood cancer survivors (CCSs) are at increased risk of developing chronic health conditions. This may potentially be reduced by a balanced diet. We aimed to compare dietary intake and diet quality using the Alternative Healthy Eating Index (AHEI) of adult CCSs and the general Swiss population. A food frequency questionnaire (FFQ) was completed by CCSs with a median age of 34 (IQR: 29-40) years. We compared dietary intake of 775 CCSs to two population-based cohorts who completed the same FFQ: 1276 CoLaus and 2529 Bus Santé study participants. CCSs consumed particular inadequate amounts of fiber and excessive amounts of sodium and saturated fat. Dietary intake was similar in CCSs and the general population. The mean AHEI was low with 49.8 in CCSs (men: 47.7, women: 51.9), 52.3 in CoLaus (men: 50.2, women: 54.0), and 53.7 in Bus Santé (men: 51.8, women: 54.4) out of a maximum score of 110. The AHEI scores for fish, fruit, vegetables, and alcohol were worse in CCSs than in the general population, whereas the score for sugar-sweetened beverages was better (all p < 0.001). Diet quality at follow-up did not differ between clinical characteristics of CCSs. Long-term CCSs and the general population have poor dietary intake and quality in Switzerland, which suggests similar population-based interventions for everyone.
- Published
- 2021
- Full Text
- View/download PDF
45. Cancer Care of Children, Adolescents and Adults With Autism Spectrum Disorders: Key Information and Strategies for Oncology Teams.
- Author
-
Vuattoux D, Colomer-Lahiguera S, Fernandez PA, Jequier Gygax M, Choucair ML, Beck-Popovic M, Diezi M, Manificat S, Latifyan S, Ramelet AS, Eicher M, Chabane N, and Renella R
- Abstract
Delivering optimal cancer care to children, adolescents and adults with ASD has recently become a healthcare priority and represents a major challenge for all providers involved. In this review, and after consideration of the available evidence, we concisely deliver key information on this heterogenous group of neurodevelopmental disorders, as well as recommendations and concrete tools for the enhanced oncological care of this vulnerable population of patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Vuattoux, Colomer-Lahiguera, Fernandez, Jequier Gygax, Choucair, Beck-Popovic, Diezi, Manificat, Latifyan, Ramelet, Eicher, Chabane and Renella.)
- Published
- 2021
- Full Text
- View/download PDF
46. Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
- Author
-
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chi Fung Chan G, Ruud E, Schroeder H, Beck-Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, and Lode HN
- Abstract
To explore the effects of immunotherapy in the International Society of Paediatric Oncology Europe Neuroblastoma Group SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1 trial), two cohorts were studied: one prior to and one after the introduction of dinutuximab beta. All patients received standard induction and high-dose therapy (HDT) with autologous stem cell rescue (ASCR); the local control comprised surgery and radiotherapy to the primary tumour site, followed by isotretinoin. A landmark timepoint of 109 days, resulting from the median time between ASCR and initiation of immunotherapy, was used to define patients' eligibility in the pre-immunotherapy analysis cohort. Median follow-up was 5.8 years (inter-quartile range (IQR): 4.2-8.2 years) for 844 eligible patients balanced for risk factors, such as age, sex, stage 4, MYCN amplification and response prior to HDT. The five-year event-free and overall survival (95% confidence interval (CI) of 466 patients not receiving immunotherapy was 42% (38-47%) and 50% (46-55%) but was 57% (51-62%) and 64% (59-69%) for 378 patients receiving immunotherapy ( p < 0.001). A multivariate analysis identified absence of immunotherapy (p = 0.0002, hazard ratio (HR) 1.573); type of HDT ( p = 0.0029, HR 1.431); less than complete response prior to maintenance therapy ( p = 0.0043, HR 1.494) and >1 metastatic compartment at diagnosis ( p < 0.001, HR 2.665) as risk factors for relapse or progression. Results suggest an important role for dinutuximab beta-based immunotherapy within the treatment concepts applied in HR-NBL1/SIOPEN., Competing Interests: The academic data supported APEIRON to obtain the dinutuximab beta product licensure in May 2017 in the European Union (EMA). SIOPEN and CCRI established a contract with APEIRON regarding the provision of academic data. Ruth Ladenstein and Holger Lode acted as consultants for APEIRON on behalf of SIOPEN for the ch14.18/CHO development. The other authors declare no conflict of interest.
- Published
- 2020
- Full Text
- View/download PDF
47. Nutritional Assessment of Childhood Cancer Survivors (the Swiss Childhood Cancer Survivor Study-Nutrition): Protocol for a Multicenter Observational Study.
- Author
-
Belle FN, Beck Popovic M, Ansari M, Otth M, Kuehni CE, and Bochud M
- Abstract
Background: Childhood cancer survivors are at high risk of developing adverse late health effects. Poor nutritional intake may contribute to this risk, but information about dietary intake is limited., Objective: This study will assess childhood cancer survivors' dietary intake and compare two dietary assessment tools: a self-reported food frequency questionnaire, and dietary measurements from urine spot samples., Methods: In a substudy of the Swiss Childhood Cancer Survivor Study (SCCSS), SCCSS-Nutrition, we assessed childhood cancer survivors' dietary intake via a validated food frequency questionnaire. We sent a urine spot collection kit to a subset of 212 childhood cancer survivors from the French-speaking region of Switzerland to analyze urinary sodium, potassium, urea, urate, creatinine, and phosphate content. We will compare the food frequency questionnaire results with the urine spot analyses to quantify childhood cancer survivors' intake of various nutrients. We collected data between March 2016 and March 2018., Results: We contacted 1599 childhood cancer survivors, of whom 919 (57.47%) returned a food frequency questionnaire. We excluded 11 childhood cancer survivors who were pregnant or were breastfeeding, 35 with missing dietary data, and 71 who had unreliable food frequency questionnaire data, resulting in 802 childhood cancer survivors available for food frequency questionnaire analyses. To a subset of 212 childhood cancer survivors in French-speaking Switzerland we sent a urine spot collection kit, and 111 (52.4%) returned a urine sample. We expect to have the results from analyses of these samples in mid-2019., Conclusions: The SCCSS-Nutrition study has collected in-depth dietary data that will allow us to assess dietary intake and quality and compare two dietary assessment tools. This study will contribute to the knowledge of nutrition among childhood cancer survivors and is a step toward surveillance guidelines and targeted nutritional recommendations for childhood cancer survivors in Switzerland., Trial Registration: ClinicalTrials.gov NCT03297034; https://clinicaltrials.gov/ct2/show/NCT03297034., International Registered Report Identifier (irrid): DERR1-10.2196/14427., (©Fabiën Belle, Maja Beck Popovic, Marc Ansari, Maria Otth, Claudia Elisabeth Kuehni, Murielle Bochud. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 18.11.2019.)
- Published
- 2019
- Full Text
- View/download PDF
48. Middle meningeal artery occlusion for intra-arterial chemotherapy of retinoblastoma.
- Author
-
Bartolini B, Puccinelli F, Hajdu SD, Stathopoulos C, Beck-Popovic M, Munier FL, and Saliou G
- Subjects
- Angiography, Digital Subtraction, Humans, Infant, Magnetic Resonance Imaging, Interventional, Male, Treatment Outcome, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Infusions, Intra-Arterial methods, Meningeal Arteries surgery, Retinal Neoplasms drug therapy, Retinoblastoma drug therapy
- Abstract
We report the intentional occlusion of the middle meningeal artery arising from the lacrimal artery, a novel technique to improve drug delivery in a 14-month-old boy with a history of right sporadic unilateral cavitary retinoblastoma group D. The patient was referred to our institution for intra-arterial chemotherapy after two systemic chemotherapy treatments. The digital subtraction angiography showed a large middle meningeal artery arising from the right lacrimal artery and decrease choroidal enhancement thus decreased flow to the tumor. The ophthalmological examination after the first intra-arterial chemotherapy observed no tumor regression. Assuming a vascular steal, in the second intra-arterial chemotherapy session, the origin of the middle meningeal artery was occluded. Following this treatment, a significant response was observed at ophthalmological follow up. In the presented case, the efficacy of intra-arterial chemotherapy was improved after occlusion of a meningeal branch arising from the lacrimal artery, which was responsible for the vascular steal.
- Published
- 2019
- Full Text
- View/download PDF
49. Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study.
- Author
-
Chatzis O, Darbre S, Pasquier J, Meylan P, Manuel O, Aubert JD, Beck-Popovic M, Masouridi-Levrat S, Ansari M, Kaiser L, Posfay-Barbe KM, and Asner SA
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Coinfection, Female, Hospitalization, Humans, Infant, Logistic Models, Male, Pneumonia, Viral therapy, Respiratory Syncytial Virus Infections diagnosis, Respiratory Tract Infections therapy, Retrospective Studies, Young Adult, Immunocompromised Host, Pneumonia, Viral virology, Respiratory Syncytial Virus Infections etiology, Respiratory Syncytial Virus Infections therapy, Respiratory Tract Infections virology
- Abstract
Background: Respiratory syncytial virus (RSV) is associated with significant mortality rates amongst hematopoietic stem cell transplant (HSCT) recipients, with less known about other immunocompromised patients., Methods: Ten-year retrospective cohort study of immunocompromised patients presenting with RSV disease documented at University Hospitals of Lausanne and Geneva. Severe RSV-related outcomes referred to RSV documented respiratory conditions requiring hospital admission, presenting as lower respiratory tract infection (LRTI) or pneumonia. We used multivariable logistic regression to assess clinical and laboratory correlates of severe RSV disease., Results: From 239 RSV-positive immunocompromised in and out-patients 175 were adults and 64 children of whom 111 (47.8%) presented with LRTI, which resulted in a 38% (89/239) admission rate to hospital. While immunocompromised children were more likely to be admitted to hospital compared to adults (75% vs 62.9%, p = 0.090), inpatients admitted to the intensive care unit (17/19) or those who died (11/11) were mainly adults. From multivariable analyses, adults with solid tumors (OR 5.2; 95% CI: 1.4-20.9 P = 0.015) or those requiring chronic immunosuppressive treatments mainly for rheumatologic conditions (OR 4.1; 95% CI: 1.1-16.0; P = 0.034) were significantly more likely to be admitted to hospital compared to hematopoietic stem cell (HSCT) recipients. Bacterial co-infection was significantly and consistently associated with viral LRTI and pneumonia., Conclusions: From our findings, RSV-related disease results in a significant burden among adults requiring chronic immunosuppressive treatments for rheumatological conditions and those with solid tumors. As such, systematic screening for respiratory viruses, should be extended to other immunocompromised populations than HSCT recipients.
- Published
- 2018
- Full Text
- View/download PDF
50. Intracameral Chemotherapy (Melphalan) for Aqueous Seeding in Retinoblastoma: Bicameral Injection Technique and Related Toxicity in a Pilot Case Study.
- Author
-
Munier FL, Gaillard MC, Decembrini S, Bongiovanni M, and Beck-Popovic M
- Abstract
Background: The anterior chamber has been shown by pharmacokinetic studies to represent a sanctuary never achieving a tumoricidal dose with the present administration routes, such as systemic, intra-arterial, or intravitreal injections., Method: A novel intracameral chemotherapy technique is described to control aqueous seeding in a pilot unilateral group E retinoblastoma case with primary aqueous seeding. Anterior segment toxicity was carefully monitored., Results: Control of the retinal tumor and vitreous seeding was achieved by intra-arterial and intravitreal chemotherapies. Sterilization of the aqueous was achieved after a first cycle of 7 melphalan injections in the anterior chamber, but relapse was noted 3.5 months later. This relapse was finally controlled with a second cycle of 6 intracameral injections targeting the posterior chamber. Corneal endothelial cell density remained stable over the injection period. Heterochromia and a progressive cataract developed, which required cataract surgery. At 5 years' follow-up, the patient is tumor free with normal vision (20/20 in both eyes), full binocularity, and no metastasis., Conclusions: The present bicameral injection technique appears to be safe and effective with limited toxicity. Melphalan-induced side effects were noted on the iris and lens but with no impact on the final visual function.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.